|
EG23659A
(en)
*
|
1995-03-24 |
2007-03-26 |
Lilly Co Eli |
Process and crystal forms of methyl-thieno-benzodiazepine
|
|
AU7013196A
(en)
*
|
1995-09-29 |
1997-04-17 |
Eli Lilly And Company |
Method for treating a tic disorder
|
|
UA57727C2
(uk)
*
|
1996-03-11 |
2003-07-15 |
Елі Ліллі Енд Компані |
Спосіб лікування надмірної агресивності
|
|
CZ290198A3
(cs)
*
|
1996-03-11 |
1999-09-15 |
Eli Lilly And Company |
Farmaceutický prostředek pro ošetřování nespavosti
|
|
CZ298398A3
(cs)
*
|
1996-03-25 |
1999-06-16 |
Eli Lilly And Company |
Farmaceutický přípravek
|
|
WO1997035585A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Eli Lilly And Company |
Anesthetic method
|
|
PL329217A1
(en)
*
|
1996-03-25 |
1999-03-15 |
Lilly Co Eli |
Pain relieving method
|
|
WO1997035586A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Eli Lilly And Company |
Method for treating pain
|
|
ZA978515B
(en)
*
|
1996-09-23 |
1999-03-23 |
Lilly Co Eli |
Intermediates and process for preparing olanzapine
|
|
CZ299247B6
(cs)
*
|
1996-09-23 |
2008-05-28 |
Eli Lilly And Company |
Olanzapin dihydrát D
|
|
ZA982917B
(en)
*
|
1997-04-15 |
1999-10-06 |
Lilly Co Eli |
Method for treating cerebral focal stroke.
|
|
US20030022889A1
(en)
*
|
1997-04-15 |
2003-01-30 |
Bymaster Franklin P. |
Method for providing neuro-protective effects
|
|
DK1155696T3
(da)
*
|
1997-04-15 |
2004-07-12 |
Lilly Co Eli |
Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
|
|
AU6955998A
(en)
*
|
1997-04-15 |
1998-11-11 |
Eli Lilly And Company |
Method for providing neuro-protective effects
|
|
USRE43932E1
(en)
|
1997-07-18 |
2013-01-15 |
Novartis Ag |
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
|
|
US6617321B2
(en)
|
1997-09-30 |
2003-09-09 |
Eli Lilly And Company |
2-methyl-thieno-benzodiazepine formulation
|
|
PL196821B1
(pl)
*
|
1998-09-30 |
2008-02-29 |
Lilly Co Eli |
Sól olanzapiny i jej zastosowanie
|
|
FR2802101B1
(fr)
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
|
US6348458B1
(en)
|
1999-12-28 |
2002-02-19 |
U & I Pharmaceuticals Ltd. |
Polymorphic forms of olanzapine
|
|
US7022698B2
(en)
|
1999-12-28 |
2006-04-04 |
U & I Pharmaceuticals, Ltd. |
Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
|
|
CA2395774C
(en)
*
|
1999-12-28 |
2009-09-15 |
Cipla Limited |
New polymorphic forms of olanzapine
|
|
SK2502003A3
(en)
*
|
2000-08-31 |
2004-03-02 |
Reddys Lab Ltd Dr |
Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
|
|
WO2002019998A2
(en)
*
|
2000-09-08 |
2002-03-14 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
|
US6740753B2
(en)
|
2001-01-04 |
2004-05-25 |
Geneva Pharmaceuticals, Inc. |
Olanzapine crystal modification
|
|
AU2002340328A1
(en)
*
|
2001-10-29 |
2003-05-12 |
Janet I. Cord |
Olanzapine dihydrate-ii a process for its preparation and use thereof
|
|
CA2471341C
(en)
*
|
2001-12-24 |
2012-01-24 |
Sun Pharmaceutical Industries Limited |
Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
|
|
WO2004089313A2
(en)
*
|
2003-04-01 |
2004-10-21 |
Transform Pharmaceuticals, Inc. |
Novel olanzapine forms and related methods of treatment
|
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
WO2004000284A1
(en)
*
|
2002-06-21 |
2003-12-31 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
|
CA2477923C
(en)
*
|
2002-03-01 |
2021-02-23 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
|
PL196814B1
(pl)
*
|
2002-05-17 |
2008-02-29 |
Inst Farmaceutyczny |
Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
|
|
US7297789B2
(en)
|
2002-05-31 |
2007-11-20 |
Sandoz, Inc. |
Process of preparation of olanzapine form I
|
|
SI21270A
(sl)
*
|
2002-07-15 |
2004-02-29 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalne oblike olanzapina in postopki za njihovo pripravo
|
|
PL202856B1
(pl)
*
|
2002-12-20 |
2009-07-31 |
Adamed Spo & Lstrok Ka Z Ogran |
Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
|
|
US7323459B2
(en)
|
2002-12-24 |
2008-01-29 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms, methods for their preparation and method for preparation of olanzapine
|
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
|
US20060135547A1
(en)
*
|
2003-03-12 |
2006-06-22 |
Toth Zoltan G |
Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
|
|
WO2004080461A2
(en)
*
|
2003-03-12 |
2004-09-23 |
TEVA Gyógyszergyár Részvénytársaság |
Stable pharmaceutical compositions of desloratadine
|
|
GB0314149D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Generics Uk Ltd |
Novel amorphous forms
|
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
|
US20070148218A1
(en)
*
|
2003-11-18 |
2007-06-28 |
Gordon Ryan D |
Olanzapine containing transdermal drug delivery compositions
|
|
DE602004014264D1
(de)
*
|
2003-12-22 |
2008-07-17 |
Teva Pharma |
Verfahren zur herstellung von olanzapin
|
|
US20050272720A1
(en)
*
|
2004-01-27 |
2005-12-08 |
Rolf Keltjens |
Process for making olanzapine Form I
|
|
ATE504588T1
(de)
|
2004-01-27 |
2011-04-15 |
Synthon Bv |
Stabile salze von olanzapin
|
|
ES2253091B1
(es)
*
|
2004-07-27 |
2007-02-01 |
Inke, S.A. |
Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
|
|
WO2006027800A1
(en)
*
|
2004-09-06 |
2006-03-16 |
Shasun Chemicals And Drugs Limited |
A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
|
|
AU2005307797B2
(en)
*
|
2004-11-16 |
2011-06-02 |
Alkermes Pharma Ireland Limited |
Injectable nanoparticulate olanzapine formulations
|
|
PL1838716T3
(pl)
|
2005-01-05 |
2011-09-30 |
Lilly Co Eli |
Dihydrat embonianu olanzapiny
|
|
CZ297214B6
(cs)
*
|
2005-02-02 |
2006-10-11 |
Zentiva, A. S. |
Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
|
|
BRPI0608484E2
(pt)
*
|
2005-03-21 |
2014-10-29 |
Reddys Lab Ltd Dr |
Processo de preparação da forma i cristalina de olanzapina
|
|
US20070021605A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Rolf Keltjens |
Process and composition for making olanzapine form i
|
|
WO2007020080A1
(en)
*
|
2005-08-17 |
2007-02-22 |
Synthon B.V. |
A process for making olanzapine form i
|
|
GB0522474D0
(en)
*
|
2005-11-03 |
2005-12-14 |
Actavis Group |
A pharmaceutical formulation
|
|
HUP0501046A2
(en)
*
|
2005-11-11 |
2007-08-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for the preparation of olanzapine
|
|
US8721202B2
(en)
|
2005-12-08 |
2014-05-13 |
Ncr Corporation |
Two-sided thermal print switch
|
|
US8222184B2
(en)
|
2006-03-07 |
2012-07-17 |
Ncr Corporation |
UV and thermal guard
|
|
US8367580B2
(en)
|
2006-03-07 |
2013-02-05 |
Ncr Corporation |
Dual-sided thermal security features
|
|
ES2279715B1
(es)
|
2005-12-26 |
2008-06-01 |
Laboratorios Lesvi, S.L. |
Formulacion oral de olanzapina.
|
|
US7834176B2
(en)
|
2006-01-26 |
2010-11-16 |
Sandoz Ag |
Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
|
|
WO2007134845A2
(en)
*
|
2006-05-18 |
2007-11-29 |
Synthon B.V. |
Olanzapine pharmaceutical composition
|
|
CL2007002807A1
(es)
*
|
2006-09-29 |
2008-04-11 |
Synthon Bv |
Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
|
|
US8039461B1
(en)
|
2006-11-10 |
2011-10-18 |
Pisgah Laboratories, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
PL381564A1
(pl)
|
2007-01-22 |
2008-08-04 |
Koźluk Tomasz Nobilus Ent |
Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
|
|
CA2591644A1
(en)
*
|
2007-06-14 |
2008-12-14 |
Apotex Pharmachem Inc. |
Novel processes to form-i of olanzapine
|
|
US9056488B2
(en)
|
2007-07-12 |
2015-06-16 |
Ncr Corporation |
Two-side thermal printer
|
|
US8883863B1
(en)
|
2008-04-03 |
2014-11-11 |
Pisgah Laboratories, Inc. |
Safety of psuedoephedrine drug products
|
|
CN101735239B
(zh)
*
|
2008-11-06 |
2011-08-31 |
齐鲁制药有限公司 |
一种无水奥氮平晶型ii的制备方法
|
|
EP2292624A1
(en)
|
2009-07-20 |
2011-03-09 |
LEK Pharmaceuticals d.d. |
Process for the purification of olanzapine
|
|
US8778960B2
(en)
|
2010-08-23 |
2014-07-15 |
Alkermes Pharma Ireland Limited |
Methods for treating antipsychotic-induced weight gain
|
|
CN102093386B
(zh)
*
|
2011-01-05 |
2016-06-01 |
浙江华海药业股份有限公司 |
一种制备奥兰扎平晶型ⅱ的方法
|
|
WO2012153347A2
(en)
|
2011-05-04 |
2012-11-15 |
Zentiva K.S. |
Oral pharmaceutical composition of olanzapine form 1
|
|
US9494608B2
(en)
|
2012-08-21 |
2016-11-15 |
Janssen Pharmaceutica Nv |
Antibodies to olanzapine and use thereof
|
|
JP6389177B2
(ja)
|
2012-08-21 |
2018-09-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
オランザピンハプテンに対する抗体及びその使用
|
|
CN104736565B
(zh)
|
2012-08-21 |
2019-03-12 |
詹森药业有限公司 |
利培酮半抗原的抗体及其用途
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
CN103848847B
(zh)
*
|
2012-12-04 |
2018-02-06 |
广东东阳光药业有限公司 |
一种改进制备奥氮平及其晶型ii的方法
|
|
JP6008734B2
(ja)
*
|
2012-12-20 |
2016-10-19 |
株式会社トクヤマ |
オランザピンｉｉ型結晶の製造方法
|
|
CN103145731B
(zh)
*
|
2013-02-26 |
2014-02-19 |
江苏豪森药业股份有限公司 |
奥氮平晶型及其制备方法和用途
|
|
KR20240130825A
(ko)
|
2022-01-20 |
2024-08-29 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
올란자핀, 이의 조성물 및 이의 사용 방법
|
|
DK4554562T3
(da)
|
2023-01-10 |
2025-12-01 |
Medincell Sa |
Olanzapinsammensætninger og fremgangsmåder til anvendelse deraf
|